Clinical Trials:

Danon Disease

RP-A501 for Danon Disease

RP-A501 is being developed for Danon Disease, a rare, genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, and for male patients, frequent death during adolescence or early adulthood.

An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. and EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months.

Trial Sites

Natural History Study

Rocket is also sponsoring a multi-center, global, non-interventional natural history study designed to collect longitudinal prospective and retrospective clinical information on patients with Danon Disease. The overarching goal of the study is to characterize the natural history of Danon Disease by collecting de-identified information from male patients with the condition. Sites for the natural history study have been identified and will enroll patients pending approval from each center’s independent review board.

For more information about Danon Disease, visit our Patients and Community page or email us at clinicaltrials@nullrocketpharma.com.

For more details about the RP-A501 for Danon Disease clinical trial, visit clinicaltrials.gov.

To read our Expanded Access statement, click here.